Introduction
A key killing mechanism used by cytotoxic T lymphocytes (CTL) and natural killer (NK) cells is the release of cytotoxic granules into the secretory synapse between effector and target cell 1 . A major constituent of these granules is the 32-kDa serine protease granzyme B 2, 3 . Granzyme B is activated by Cathepsin C after its release into the secretory synapse, taken up into the target cell via fluid phase and mannose-6-phosphate receptor-mediated endocytosis 2 , and released from the endosome in response to a second signal, such as perforin, or microbial factors such as adenovirus or certain bacterial toxins [4] [5] [6] [7] . The transduction of the death signal mediated by granzyme B in the target cell occurs via two pathways, one by direct signaling to the mitochondria via BID and one by activation of the classical caspase cascade. Granzyme B is one of the most effective and fastest executioners of apoptosis known. To date, CTL and NK cells are the cell populations known to express and secrete granzyme B.
B chronic lymphocytic leukemia (B-CLL) is the most prevalent leukemia in the western world and is characterized by the progressive accumulation of malignant B cells in peripheral blood, secondary lymphoid tissue and bone marrow. In the majority of cases, B-CLL cells are positive for the T cell marker CD5 and are therefore easily detectable by flow cytometry and immunohistochemistry 8, 9 . Despite recent development of a number of effective agents, B-CLL is generally considered incurable, and there is a need for targeted agents or combinations.
Therapy of B-CLL with a variety of cytokines and other immunostimulatory agents is under evaluation based on the understanding that signals which induce proliferation of benign B
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From cells can sometimes induce apoptosis of malignant B cells. For example, Interleukin 21 (IL-21) is a novel IL-2 family cytokine produced by activated CD4+ T cells. IL-21 has pleiotropic effects on B, T and NK cells [10] [11] [12] . In primary human B cells, IL-21 enhances anti-CD40-mediated proliferation. A recent report indicates the combination of IL-21 plus anti-CD40 induces apoptosis of B-CLL cells 13 . We have evaluated the effect of the TLR9 ligand CpG ODN on B-CLL cells, and found it activates and induces proliferation of benign B cells, but is capable of inducing apoptosis in most B-CLL samples [14] [15] [16] [17] [18] . While caspase activation is a common pathway observed in the apoptosis of B-CLL induced by both IL-21 and CpG
ODN, the precise apoptotic signals that lead to caspase activation for these agents is not known.
We therefore evaluated the combination of IL-21 and CpG ODN for their effect on B-CLL cells, and assessed how such treatment might lead to death of the B-CLL cells. As outlined below, we found these agents were synergistic in their ability to induce apoptosis of B-CLL For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From
Materials and Methods

Human subjects and cell culture
Peripheral blood from a total of 17 different subjects with B-CLL and 16 different healthy subjects was acquired after obtaining informed consent from each individual. Use of blood from healthy human subjects and subjects with B-CLL for the study described in this paper was approved by the Institutional Review Board at the University of Iowa. B-CLL subjects were heterogeneous, but consisted mostly of newly diagnosed subjects with early phase disease (n=14). Three subjects with more advanced disease who had previously been treated with Fludarabine and Cytoxan were also tested. None were under treatment at the time the samples were obtained. Mononuclear cells were immediately isolated, and red blood cells -TCG TCG TTT TGT   CGT TTT GTC GTT-3', CONTROL ODN: 5'-GGG GGA GCA TGC TGG GGG GG-3'. ODN were diluted in TE (10 mM Tris-HCl, 1 mM EDTA, pH 8) using pyrogen-free reagents, and used at a final concentration (fc) of 2.5 µg/ml. Human IL-21 (fc: 100 ng/ml) was purchased from BioSource (Camarillo, CA), IL-2 (fc: 100 U/ml) was purchased from Peprotech (Rocky Hill, NJ). B cell receptor stimulation was performed using affinity purified rabbit F(ab') 2 fragments against human IgA+IgG+IgM (H+L) (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA; fc: 10 µg/ml). 
Reagents for functional assays
Flow cytometry
For staining of surface markers, cells were harvested at the indicated time points and stained as described previously 19 . Antibodies to CD5, CD19, and CD107a were purchased from BD Bioscoences (San Diego, CA). IL-21 receptor protein expression was detected using a mAB (clone 152512) from R&D Systems (Minneapolis, MN). PKH26, a red fluorescent dye used for general cell membrane labeling, was used to identify untreated cells in bystander assays.
B-CLL cells were resuspended at a density of 1x10 7 cells/ml in diluent C containing 2 µM PKH26 (both from Sigma, Saint Louis, MO). After 3 minutes, the reaction was stopped by adding an equal volume of FBS (HyClone, Ogden, UT). Cells were washed 3 times and 
Elispot assays for human granzyme B
Human granzyme B Elispot kits were purchased from Cell Sciences, (Canton, MA). PVDFbottomed 96-well plates were purchased from Millipore (Bedford, MA,). The assays were performed according to the manufacturer's protocol. Briefly, plates were prepared by adding the capture antibody and blocking with 2% skim milk in PBS, then cells were resuspended in AIM-V medium, plated (100µl/well), and CpG ODN (2.5µg/ml), IL-21 (100ng/ml), anti-BCR (10 µg/ml) or combinations of these agents were added and cultured for 16 hours.
Freshly isolated PBMC stimulated with PHA (10 µg/ml) served as a positive control. After culture, the detection antibody was added and plates incubated for 1.5 hours. Streptavidinalkaline phosphatase was distributed, and plates incubated for 1hr. Finally BCIP/NBT buffer was added and color was allowed to develop for 10 minutes at room temperature followed by rinsing with distilled water. Plates were dried completely, and spots read on an Immunospot 
Microarray Profiling
B-CLL cells were isolated from other cells by magnetic beads as outlined above, and cultured in media or 2.5 µg/ml CpG ODN for 2 hours. RNA was isolated using Trizol (Invitrogen, Grand Island, NY) followed by the RNeasy Kit (Qiagen, Valencia, CA) used according to the manufacturer's specifications. Subsequently, the RNA sample was concentrated to 7 mg/ml by centrifugation on a filtration concentrator to clean-up the RNA. The RNA concentration was determined by spectrophotometry and RNA stored at -80ºC. Gene expression profiling was conducted in the University of Iowa DNA Core. Gene profiles were generated according to manufacturer guidelines for the U133A chip (Affymetrix, Inc., Santa Clara, CA). Quality control test arrays include an Affymetrix test chip containing housekeeping genes (e.g. GAPDH, β-actin) with targets corresponding to various regions of the gene from 3' to 5'. The signal was assessed for discrepancies from 3' to 5', and if the signal was more than 3-fold different, the sample failed quality control and was prepared again. Intensity values were normalized using Affymetrix MAS 5. After normalization, data analysis was carried out in R (R Development Core 2005).
General statistical analysis
Data are expressed as means ± SEM. To determine statistical differences between the means of two data columns, the paired Student's t-test was used. A p value of < 0.05 was considered to be significant, a p value of < 0.005 was considered to be highly significant. Isobolographic analysis was performed using FlashCalc version 20.5 (FlashCalc Pharmacologic calculations,
M.H. Ossipov, Tucson, AZ).
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Results
CpG ODN induces upregulation of the IL-21 receptor by B-CLL cells.
We and others have found that CpG ODN can induce apoptosis, and alter the phenotype of B-CLL cells [15] [16] [17] [18] 20, 21 . B-CLL cells also have receptors for, and respond to a variety of Interleukin-2-related cytokines including IL-2, IL-15 and IL-21 13, 22, 23 . The ability of CpG ODN to alter expression of these receptors had not been studied previously. We therefore Measurement of apoptosis after 12 hours using DNA fragmentation as measured by flow cytometric TUNEL analysis gave similar results (Supplemental Figure 2) . In contrast to IL-21, IL-2 did not induce apoptosis of B-CLL when combined with CpG ODN. The ability of varying doses of IL-21 and CpG ODN to induce apoptosis was also assessed. The ED 50 for each agent alone was identified (IL-21: 40 ng/ml; CpG ODN: 0.4 µg/ml) and the interaction between these agents determined as described by Tallarida et al. 24 . Isobolographic analysis demonstrated that the combined pro-apoptotic effect of IL-21 and CpG ODN on B-CLL cells is synergistic ( Figure 2A+B ).
For
IL-21 and CpG ODN induce apoptosis of highly purified B-CLL cells.
For For 
Effect of IL-21 and other B cell activators on B-CLL cells.
Combinations of other B cell stimulatory agents were also tested for their ability to induce 
B-CLL cells treated with CpG ODN and IL-21 can kill untreated autologous cells.
Bystander killing is blocked by anti-granzyme B antibody.
We next evaluated whether B-CLL cells treated with IL-21 and CpG ODN have the potential to kill. To avoid the complexity of dealing with an allogenic interaction, this was done using autologous B-CLL cells. Purified B-CLL cells were split into two fractions. One fraction was stained with the membrane dye PKH26 to enable us to differentiate treated from untreated cells, and incubated for 24 hours with IL-21 and CpG ODN. These stained, treated cells were washed three times to remove the agents, and mixed with the unstained, untreated fraction for 2 days. The survival of the unstained, untreated cells was then evaluated by flow cytometry. As illustrated in Figure 6A+B , the cells treated with IL-21 and CpG ODN 
IL-21 and anti-BCR can induce granzyme B production by other B cell populations including benign B cells, EBV-transformed B cells, and B cell lines.
Isolated peripheral blood B cells from normal donors, EBV-transformed lymphoblasts, and standard human lymphoma cell lines were evaluated for their response to IL-21 and CpG ODN or anti-BCR using Elispot (Figure 7) . The combination of IL-21 and anti-BCR had no effect on Raji cells, but induced a significant degree of granzyme B production by Ramos, PBMC from 9 subjects with B-CLL were cultured for 4 days in the presence of CpG ODN (2.5 µg/ml) and IL-21 (100 ng/ml) or IL-2 (100 U/ml). Cell survival of B-CLL cells was determined using Annexin V and PI staining and counterstaining with antibodies to CD19. 
